Abstract: The present disclosure relates to determining an efficacy of a therapeutic agent. A method for determining an efficacy of a therapeutic agent for a target disease can include measuring a molecular structure of a biological tissue of an animal at a first time and at a second time using a non-invasive biological tissue characterization technique. The method can further include observing a change of the molecular structure of the biological tissue between the first time and the second time, and determining the efficacy of the therapeutic agent based on the observed change in the molecular structure of the biological tissue. Before the first time, or between the first time and the second time, the animal received the therapeutic agent.

Abstract: The present disclosure relates to determining a biological tissue structural marker for diagnosis of a disease using a biological tissue characterization technique. A method for determining a structural marker for a diagnosis of a disease can include measuring a first molecular structure of a biological tissue of a first population of animals, after a carcinogenic or pathogenic substance was introduced into the first population. A second molecular structure of the biological tissue of a second population of animals can be measured, wherein the second population did not receive the carcinogenic or pathogenic substance. A first and a second structural marker of the molecular structures of the biological tissue of the first and second populations, respectively, can be identified and compared to determine that the first structural marker is indicative that the biological tissue of the first population of animals was affected by the disease.

Abstract: The present disclosure relates to determining a therapy efficacy. A method for determining an efficacy of a therapy for a disease in an animal patient can include measuring a molecular structure of a biological tissue of an animal patient at a first time and at a second time using a non-invasive biological tissue characterization technique. The method can further include observing a change of the molecular structure of the biological tissue between the first time and the second time, and determining the efficacy of the therapy based on the observed change in the molecular structure of the biological tissue. Before the first time, or between the first time and the second time, the animal patient received the therapy.

Abstract: An animal-tissue analysis and communication system produces a quantitative-diagnostic indicator for animal-tissue analyzed by the system. The system includes an animal-tissue-analyzer subsystem with at least one animal-tissue analyzer constructed to analyze animal tissue and to produce an quantitative-diagnostic indicator. The system also includes a two-way communication subsystem constructed to allow the animal-tissue-analyzer subsystem to send and receive information relevant to the quantitative-diagnostic indicator. The animal-tissue-analyzer subsystem includes at least one tissue diffractometer operatively coupled to a computer database over a network, and is configured for acquisition and transfer of animal-tissue data, and transfer to the computer database over the network.